A breakthrough UK tech is set to revolutionize the way women in England receive a diagnosis for possible womb cancer by potentially replacing traditional invasive checks. The innovative solution uses artificial intelligence (AI) to analyze blood samples from referred patients, assessing their risk of developing cancer and making informed decisions about further testing.
According to reports, around 90,000 postmenopausal women are referred each year to NHS hospitals for tests after experiencing heavy bleeding, a common symptom associated with womb cancer. However, invasive checks typically follow this referral, raising concerns about unnecessary procedures and potential complications. The AI blood test aims to alleviate these concerns by providing a more accurate and timely diagnosis.
The technology is expected to reduce the number of invasive tests carried out on patients while also saving time and resources for healthcare providers. This development could mark a significant shift in the way women are treated for womb cancer, offering better outcomes and improved patient experiences. The NHS AI blood test is still in its pilot phase, but it has already demonstrated promising results in various clinical trials.